Tomonori Tsuyama

Dr. Tomonori Tsuyama

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2023 in EMBO Reports
Verified
Journal Article
Closed access
TTTomonori Tsuyama
Tomonori Tsuyama
YSYoshifumi Sato
Yoshifumi Sato
TYTatsuya Yoshizawa
Tatsuya Yoshizawa
TMTakaaki Matsuoka
Takaaki Matsuoka
KYKazuya Yamagata
Kazuya Yamagata

Verified
Journal Article
Open access
PDF file
KYKazuya Yamagata
Kazuya Yamagata
TTTomonori Tsuyama
Tomonori Tsuyama
YSYoshifumi Sato
Yoshifumi Sato
Type 2 diabetes is a chronic disease marked by hyperglycemia; impaired insulin secretion by pancreatic β-cells is a hallmark of this disease. Recent studies have shown that hypoxia occurs in the β-cells of patients with type 2 diabetes and hypoxia, in turn, contributes to the insulin secretion defect and β-cell loss through various mechanisms, including the activation of hypoxia-inducible factors, induction of transcriptional repressors, and activation of AMP-activated protein kinase. This review focuses on advances in our understanding of the contribution of β-cell hypoxia to the development of β-cell dysfunction in type 2 diabetes. A better understanding of β-cell hypoxia might be useful in the development of new strategies for treating type 2 diabetes.

17 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KKKazuhide Kikawa
Kazuhide Kikawa
DSDaisuke Sakano
Daisuke Sakano
NSNobuaki Shiraki
Nobuaki Shiraki
TTTomonori Tsuyama
Tomonori Tsuyama
KKKazuhiko Kume
Kazuhiko Kume
SKShoen Kume
Shoen Kume
Islet transplantation is a promising potential therapy for patients with type 1 diabetes. The outcome of islet transplantation depends on the transplantation of a sufficient amount of β-cell mass. However, the initial loss of islets after transplantation is problematic. We hypothesized the hyperglycemic status of the recipient may negatively affect graft survival. Therefore, in the present study, we evaluated the effect of insulin treatment on islet transplantation involving a suboptimal amount of islets in Akita mice, which is a diabetes model mouse with an Insulin 2 gene missense mutation. Fifty islets were transplanted under the left kidney capsule of the recipient mouse with or without insulin treatment. For insulin treatment, sustained-release insulin implants were implanted subcutaneously into recipient mice 2 weeks before transplantation and maintained for 4 weeks. Islet transplantation without insulin treatment did not reverse hyperglycemia. In contrast, the group that received transplants in combination with insulin treatment exhibited improved fasting blood glucose levels until 18 weeks after transplantation, even after insulin treatment was discontinued. The group that underwent islet transplantation in combination with insulin treatment had better glucose tolerance than the group that did not undergo insulin treatment. Insulin treatment improved graft survival from the acute phase (i.e., 1 day after transplantation) to the chronic phase (i.e., 18 weeks after transplantation). Islet apoptosis increased with increasing glucose concentration in the medium or blood in both the in vitro culture and in vivo transplantation experiments. Expression profile analysis of grafts indicated that genes related to immune response, chemotaxis, and inflammatory response were specifically upregulated when islets were transplanted into mice with hyperglycemia compared to those with normoglycemia. Thus, the results demonstrate that insulin treatment protects islets from the initial rapid loss that is usually observed after transplantation and positively affects the outcome of islet transplantation in Akita mice.

15 November 2022 in Cells
Verified
Journal Article
Open access
PDF file
TMTomoya Mizumoto
Tomoya Mizumoto
TYTatsuya Yoshizawa
Tatsuya Yoshizawa
YSYoshifumi Sato
Yoshifumi Sato
TITakaaki Ito
Takaaki Ito
TTTomonori Tsuyama
Tomonori Tsuyama
KYKazuya Yamagata
Kazuya Yamagata
Sirtuins (SIRT1–7 in mammals) are evolutionarily conserved nicotinamide adenine dinucleotide-dependent lysine deacetylases/deacylases that regulate fundamental biological processes including aging. In this study, we reveal that male Sirt7 knockout (KO) mice exhibited an extension of mean and maximum lifespan and a delay in the age-associated mortality rate. In addition, aged male Sirt7 KO mice displayed better glucose tolerance with improved insulin sensitivity compared with wild-type (WT) mice. Fibroblast growth factor 21 (FGF21) enhances insulin sensitivity and extends lifespan when it is overexpressed. Serum levels of FGF21 were markedly decreased with aging in WT mice. In contrast, this decrease was suppressed in Sirt7 KO mice, and the serum FGF21 levels of aged male Sirt7 KO mice were higher than those of WT mice. Activating transcription factor 4 (ATF4) stimulates Fgf21 transcription, and the hepatic levels of Atf4 mRNA were increased in aged male Sirt7 KO mice compared with WT mice. Our findings indicate that the loss of SIRT7 extends lifespan and improves glucose metabolism in male mice. High serum FGF21 levels might be involved in the beneficial effect of SIRT7 deficiency.

9 October 2025 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Closed access
STShuntaro Tanimura
Shuntaro Tanimura
TTTakuya Tokunaga
Takuya Tokunaga
JKJunki Kawakami
Junki Kawakami
XTXiao Tian
Xiao Tian
HGHikaru Goshogawa
Hikaru Goshogawa
TMTakeshi Miyamoto
Takeshi Miyamoto

28 April 2026 in Anticancer Research
Verified
Journal Article
Closed access
TTTomonori Tsuyama
Tomonori Tsuyama
HDHanchen Dong
Hanchen Dong
TSTakenari Sato
Takenari Sato
HOHirohisa Okabe
Hirohisa Okabe
HHHiromitsu Hayashi
Hiromitsu Hayashi
KYKazuya Yamagata
Kazuya Yamagata
Epidemiological studies have demonstrated that type 2 diabetes mellitus (T2DM) is a risk factor for pancreatic ductal adenocarcinoma (PDAC); however, the underlying mechanisms remain unclear. Recent studies have suggested a potential link between proinsulin, a prohormone of insulin, and cancer. In this study, we examined the tumorigenic effects of proinsulin in PDAC. We measured the expression levels of the insulin receptor (IR) gene isoforms IR-A and IR-B in tumor samples from 5 patients with PDAC and in the human PANC-1 pancreatic adenocarcinoma cell line using reverse transcription-PCR. We then assessed the effect of proinsulin treatment on ERK and AKT phosphorylation in PANC-1 cells using western blotting. We also evaluated the effect of proinsulin treatment on cell proliferation, resistance to an anti-cancer drugs, and cell invasion using direct cell counting and a WST-1 assay, an annexin/propidium iodine cell death detection assay, and an invasion assay, respectively. Finally, we used RNA sequencing and quantitative reverse transcription-PCR to identify genes whose expression was altered by proinsulin treatment. IR-A was expressed in tumor tissues from four out of five PDAC patients and in PANC-1 cells. Proinsulin stimulation significantly increased ERK1/2 phosphorylation in PANC-1 cells and also increased AKT phosphorylation, albeit to a lesser extent. Proinsulin stimulation significantly induced cell proliferation, protected against staurosporine-induced apoptosis, and promoted PANC-1 cell invasion. Consistent with these results, proinsulin stimulation upregulated the expression of genes related to cell proliferation, anti-cancer drug resistance, and cell invasion in PANC-1 cells. Proinsulin may promote PDAC tumor development by binding to IR-A and activating the ERK pathway.